Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin’s lymphoma

Journal for ImmunoTherapy of Cancer · Published 2026-07-01 · DOI 10.1136/jitc-2025-014311

Free full text

Authors (26)

Farrukh T Awan, Joshua T Gamse, Marije B Overdijk, Esther C W Breij, Maria Jure-Kunkel, Kinjal Sanghavi, Lauren K Brady, Meijian Guan, Inge Verbrugge, Jenny Chen, Nian Gong, Michael Gillespie, Michael Tees, Molly Gallogly, Martin Hutchings, Jacob Haaber Christensen, Anna Sureda, Raul Cordoba, Sairah Ahmed, F J Sherida H Woei-A-Jin, Pau Abrisqueta, Eva Giné, Michael Roost Clausen, Seema A Bhat, Ajay K Gopal, Martine E D Chamuleau

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Awan, F., Gamse, J., Overdijk, M., et al. (2026). Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin’s lymphoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014311

Related articles